Q3 2022 net loss was $(0.27) per basic and diluted share and adjusted non-GAAP net income was $1.13 per basic and $1.12 per diluted share1
Total revenue for Q3 2022 was $65.9 million, compared to $39.9 million in Q3 2021
Nine-month 2022 net income was $2.41 per basic and $2.38 per diluted share
Nine-month 2022 adjusted non-GAAP earnings per diluted share1 more than doubled to $6.69 from full year 2021 adjusted non-GAAP earnings per diluted share, outperforming any full year in the Company’s history
Nine-month 2022 revenue of $255.9 million exceeds full year 2021 revenue of $171.5 million
Nine-month 2022 net sales of vasopressin and PEMFEXY combined totaled $114.9 million
BENDEKA®2 and BELRAPZO®3 - both ready-to-dilute (“RTD”) products — combined currently have 91% share of the bendamustine market, up from 85% at the beginning of the year. TREANDA®4, which is not an RTD product, has just 9%5
Q3 2022 gross profit from bendamustine franchise increased 9% compared to Q3 20216
Submitted an investigational new drug (“IND”) application to the U.S. Food and Drug Administration (“FDA”) for CAL02, a novel first-in-class broad-spectrum anti-virulence agent for the treatment of severe community-acquired bacterial pneumonia
Strengthened hospital pipeline through equity stake in and an option to acquire Enalare Therapeutics Inc (“Enalare”)7. Enalare’s lead pipeline compound, ENA-001, a novel agnostic respiratory stimulant with strong patent protection, has three target indications: post-operative respiratory depression; community drug overdose; and Apnea of Prematurity, a common condition in preterm infants
Company to host Investor Day in New York City on December 6, 2022
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.